ExeVir and Mithra announce manufacturing collaboration for innovative Covid-19 treatments
#Accelerated clinical development of ExeVir’s novel llama-derived antibody therapies for potential treatment and prevention of Covid-19.
#Manufacturing of ExeVir’s candidate product at Mithra CDMO’s new Injectable Facility
#Joint unique expertise of two Belgian biotechs to provide global access to innovative therapies for a broad range of coronaviruses, including variants of concern
15 July 2021, 07:30 CEST, Belgium – ExeVir, which is developing single domain antibody therapies providing broad protection against viral infections, and Mithra Pharmaceuticals (Euronext Brussels: MITRA) announce a new collaboration to utilize the fill and finish capabilities for ExeVir’s innovative therapies at Mithra’s integrated R&D and manufacturing platform, Mithra CDMO.
"We are very pleased to collaborate with Mithra which has built a cutting-edge new fill and finish manufacturing facility. It has been a phenomenal year for ExeVir. Being able to collaborate with great partners in Europe such as Mithra and others are not only key to our success, but also helps the growth of the biotech ecosystem in Belgium and across Europe."
Torsten Mummenbrauer, CEO of ExeVir Bio